Global Prothrombin Complex Concentrate (PCC) Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Prothrombin Complex Concentrate (PCC) Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Prothrombin complex concentrate (PCC), also known as factor IX complex, is a medication made up of blood clotting factors II, IX, and X. Some versions also contain factor VII. It is used to treat and prevent bleeding in hemophilia B if pure factor IX is not available. It may also be used in those with not enough of these factors due to other reasons such as warfarin therapy. It is given by slow injection into a vein.
Prothrombin Complex Concentrate (PCC) Drug report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Prothrombin Complex Concentrate (PCC) Drug market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hemophilia B and Acquired Coagulation Factor Deficiency are the major drivers for the industry.
In Europe and United States market, key players of prothrombin complex concentrate (PCC) drug include CSL Behring, Grifols, Octapharma, Prothya Biosolutions, Takeda, etc. The top one player hold a share about 58%. United States is the largest market, has a share about 47%, followed by Germany, and France, with share 13% and 12%, separately.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Prothrombin Complex Concentrate (PCC) Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
CSL Behring
Grifols
Octapharma
Prothya Biosolutions
Takeda
Segment by Type
Beriplex
Profilnine
Octaplex
Prothromplex
Cofact
Other
Hemophilia B
Acquired Coagulation Factor Deficiency
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Prothrombin Complex Concentrate (PCC) Drug market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Prothrombin Complex Concentrate (PCC) Drug, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Prothrombin Complex Concentrate (PCC) Drug industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Prothrombin Complex Concentrate (PCC) Drug in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Prothrombin Complex Concentrate (PCC) Drug introduction, etc. Prothrombin Complex Concentrate (PCC) Drug Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Prothrombin Complex Concentrate (PCC) Drug market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Prothrombin Complex Concentrate (PCC) Drug report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Prothrombin Complex Concentrate (PCC) Drug market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hemophilia B and Acquired Coagulation Factor Deficiency are the major drivers for the industry.
In Europe and United States market, key players of prothrombin complex concentrate (PCC) drug include CSL Behring, Grifols, Octapharma, Prothya Biosolutions, Takeda, etc. The top one player hold a share about 58%. United States is the largest market, has a share about 47%, followed by Germany, and France, with share 13% and 12%, separately.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Prothrombin Complex Concentrate (PCC) Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
CSL Behring
Grifols
Octapharma
Prothya Biosolutions
Takeda
Segment by Type
Beriplex
Profilnine
Octaplex
Prothromplex
Cofact
Other
Segment by Application
Hemophilia B
Acquired Coagulation Factor Deficiency
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Prothrombin Complex Concentrate (PCC) Drug market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Prothrombin Complex Concentrate (PCC) Drug, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Prothrombin Complex Concentrate (PCC) Drug industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Prothrombin Complex Concentrate (PCC) Drug in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Prothrombin Complex Concentrate (PCC) Drug introduction, etc. Prothrombin Complex Concentrate (PCC) Drug Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Prothrombin Complex Concentrate (PCC) Drug market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices